Biotech Values

[swampboots]

Last few of my posts happen to be tracking the unmet solid tumor "discoveries" plus this one out today.
Would think they have room to tighten up efficacy of this initiative they have (with flurry of added theoretical platforms).but they seem to be spending close to 300 million a year to stay in game while they still have a 2 billion dollar market cap. Against their hope to reward shareholders as well as contribute to science, there is almost no history of final lasting success conquering their solid tumor targets, albeit "lasting" success can be swayed and proportioned to mingle with further investment credibility.
https://medicalxpress.com/news/2022-05-tracking-t-cell-boosts-immune-disease.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter